AU1278701A - Novel compounds - Google Patents

Novel compounds

Info

Publication number
AU1278701A
AU1278701A AU12787/01A AU1278701A AU1278701A AU 1278701 A AU1278701 A AU 1278701A AU 12787/01 A AU12787/01 A AU 12787/01A AU 1278701 A AU1278701 A AU 1278701A AU 1278701 A AU1278701 A AU 1278701A
Authority
AU
Australia
Prior art keywords
novel compounds
compounds
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12787/01A
Inventor
Steven Mark Bromidge
Halina Teresa Serafinowska
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GBGB9926302.2A priority Critical patent/GB9926302D0/en
Priority to GB9926302 priority
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to PCT/EP2000/010911 priority patent/WO2001032646A2/en
Publication of AU1278701A publication Critical patent/AU1278701A/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
AU12787/01A 1999-11-05 2000-11-02 Novel compounds Abandoned AU1278701A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB9926302.2A GB9926302D0 (en) 1999-11-05 1999-11-05 Novel compounds
GB9926302 1999-11-05
PCT/EP2000/010911 WO2001032646A2 (en) 1999-11-05 2000-11-02 Sulfonamide derivatives

Publications (1)

Publication Number Publication Date
AU1278701A true AU1278701A (en) 2001-05-14

Family

ID=10864071

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12787/01A Abandoned AU1278701A (en) 1999-11-05 2000-11-02 Novel compounds

Country Status (5)

Country Link
EP (1) EP1228066A2 (en)
JP (1) JP2003513085A (en)
AU (1) AU1278701A (en)
GB (1) GB9926302D0 (en)
WO (1) WO2001032646A2 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011083A (en) 2001-06-11 2004-07-08 Biovitrum Ab Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes.
JP4187650B2 (en) 2001-08-10 2008-11-26 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 5-HT6 arylsulfonyl derivatives with receptor affinity
SE0103644D0 (en) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
JP2005511594A (en) 2001-11-09 2005-04-28 ビオヴィトルム・アクチボラゲットBiovitrum AB The use of sulfonamide derivatives for reduction of the treatment of obesity, or food intake
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
CA2474214A1 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
KR20040081201A (en) * 2002-02-13 2004-09-20 글락소 그룹 리미티드 Bezenesulfonamide Derivatives As Antipsychotic Agents
EP1495004A2 (en) * 2002-02-13 2005-01-12 Glaxo Group Limited Benzenesulfonamide derivatives and their use as dopamine d3 and d2 receptor ligands
DE60304695T2 (en) * 2002-02-13 2006-09-21 Glaxo Group Ltd., Greenford 7-arylsulfonamido-2,3,4,5-tetrahydro-1H-benzo [d] azepine derivatives having 5-HT-6 receptor affinity for treating diseases of the central nervous system
AT398108T (en) 2002-03-27 2008-07-15 Glaxo Group Ltd Quinoline derivatives and their use as 5-HT6 ligands
MXPA04011465A (en) 2002-05-24 2005-02-14 Millennium Pharm Inc Ccr9 inhibitors and methods of use thereof.
JP4754821B2 (en) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッドProximagen Limited Obesity, novel compounds useful in the treatment of ii diabetes mellitus and cns disorders
AU2003243091A1 (en) * 2002-06-20 2004-01-06 Biovitrum Ab (Publ) New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
EP1897876A3 (en) 2002-06-20 2009-03-18 Biovitrum AB (publ) Compounds useful for the treatment of obesity, type II diabetes and CNS disorders
EP1549639B1 (en) 2002-10-07 2006-05-24 Glaxo Group Limited Sulphonamide derivatives as antipsychotic agents
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
PT1798223E (en) 2002-11-18 2011-10-17 Chemocentryx Inc Aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
DK1620437T3 (en) 2003-04-29 2009-08-24 Pfizer Ltd 5,7-diaminopyrazolo-4,3-d-pyrimidines that are useful for treating hypertension
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
ES2222832B1 (en) 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. 6-indolilsulfonamidas derivatives, their preparation and their use as medicaments.
ES2222829B1 (en) 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 4-indolilsulfonamidas derivatives, their preparation and their use as medicaments.
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
SE0303480D0 (en) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
BRPI0417833A (en) * 2003-12-19 2007-04-17 Biovitrum Ab new benzofuran derivatives, which can be used in the prophylaxis or treatment of disorders related to the 5-HT6 receptor
EP1742950B1 (en) 2004-04-07 2008-12-17 Pfizer Limited Pyrazolo[4,3-d] pyrimidines
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
EP1676841A1 (en) * 2004-12-30 2006-07-05 Esteve Laboratorios Dr. Esteve S.A. Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments
BRPI0613564A2 (en) 2005-07-04 2011-01-18 Novo Nordisk As compounds, their use in the preparation of pharmaceutical compositions and pharmaceutical compositions comprising the same
JP2009500406A (en) * 2005-07-05 2009-01-08 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag The novel compounds, processes for their preparation, intermediates, pharmaceutical compositions, as well as Alzheimer's disease, cognitive impairment, cognitive impairment associated with schizophrenia, their use in the treatment of 5-HT6 mediated disorders such as obesity and Parkinson's disease
JP2009501705A (en) * 2005-07-05 2009-01-22 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag The novel compounds, processes for their preparation, intermediates, pharmaceutical compositions, as well as Alzheimer's disease, cognitive impairment, cognitive impairment associated with schizophrenia, their use in the treatment of 5-HT6 mediated disorders such as obesity and Parkinson's disease
NZ566495A (en) 2005-08-12 2010-06-25 Suven Life Sciences Ltd Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands
WO2007020654A1 (en) 2005-08-16 2007-02-22 Suven Life Sciences An improved process for the preparation of losartan
WO2007108744A2 (en) * 2006-03-17 2007-09-27 Astrazeneca Ab Novel quinazolines as 5-ht6 modulators
WO2007108743A2 (en) * 2006-03-17 2007-09-27 Astrazeneca Ab Novel quinazolines as 5-ht6 modulators ii
EP1837332A1 (en) * 2006-03-23 2007-09-26 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydroisoquinoline compounds, their preparation and use in medicaments
WO2007137968A1 (en) 2006-05-29 2007-12-06 High Point Pharmaceuticals, Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
CA2667857A1 (en) 2006-10-30 2008-05-08 Biovitrum Ab (Publ) 8-sulfonyl-1, 3, 4, 8-tetrahydr0-2h- [1, 4] oxazepino [6, 7-e] indole derivatives and their use as 5-ht6 receptor ligands
EP2114878B1 (en) 2007-01-08 2010-12-15 Suven Life Sciences Limited 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands
CA2683124C (en) 2007-05-03 2012-09-25 Suven Life Sciences Limited Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
EP2014656A3 (en) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
DE102007042154A1 (en) * 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure derivatives, their preparation and their use as medicaments
AT518833T (en) 2007-10-26 2011-08-15 Suven Life Sciences Ltd Aminoarylsulfonamidverbindungen and their use as 5-HT6 ligands
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
CN101952278A (en) * 2008-02-15 2011-01-19 弗·哈夫曼-拉罗切有限公司 3-alkyl-piperazine derivatives and uses thereof
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2116547A1 (en) * 2008-05-09 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands
WO2010032257A1 (en) 2008-09-17 2010-03-25 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands
KR101308819B1 (en) 2008-09-17 2013-09-13 수벤 라이프 사이언시스 리미티드 Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CA2786072C (en) 2010-01-05 2014-10-28 Suven Life Sciences Limited Sulfone compounds as 5-ht6 receptor ligands
US9840482B2 (en) 2014-04-19 2017-12-12 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof
KR20180022792A (en) 2015-06-12 2018-03-06 엑소반트 사이언시즈 게엠베하 RAM useful diaryl and aryl in the prevention and treatment of sleep behavior disorder heteroaryl urea derivatives
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0689536T3 (en) * 1993-03-16 2001-07-30 Pfizer naphtahlene
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Sulfonamide derivatives new method for leurpréparation and pharmaceutical compositions ontaining c.

Also Published As

Publication number Publication date
EP1228066A2 (en) 2002-08-07
WO2001032646A2 (en) 2001-05-10
WO2001032646A3 (en) 2001-12-27
GB9926302D0 (en) 2000-01-12
JP2003513085A (en) 2003-04-08

Similar Documents

Publication Publication Date Title
GB9905124D0 (en) Novel compounds
AU2002246855A1 (en) Novel compounds
AU2002218266A1 (en) Novel indanylidene compounds
AU6587000A (en) Composition
AU5406600A (en) Microcapsules - i
AU6265000A (en) Microcapsules - iii
AU5977300A (en) Microcapsules - ii
AU1173201A (en) Skin-gripper
AU2001274763A1 (en) Novel compounds
AU6113200A (en) Conditional-selex
AU3092999A (en) Digital-timeshare-exchange
AU5413600A (en) Compounds
AU5414000A (en) Compounds
AU1529901A (en) Compounds
AU5986200A (en) Compounds
AU2001271434A1 (en) Novel skateboard-bicycle combination
AU6825300A (en) Compounds
AU1278701A (en) Novel compounds
GB9914371D0 (en) Novel compounds
AU2678800A (en) Modified calycins
GB9908647D0 (en) Novel compounds
AU1996301A (en) Novel heteroaryl-diazabicycloalkanes
AU4431000A (en) Novel use
GB9910079D0 (en) Novel compounds
GB9911594D0 (en) Novel compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase